1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Naloxone Hydrochloride Injection, USP (Hospira Inc.)
Trade Name: Naloxone Hydrochloride Injection
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROCHLORIC ACID</td>
<td>7647-01-0</td>
<td>231-595-7</td>
<td>Skin Corr.1B (H314)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>STOT SE 3 (H335)</td>
<td></td>
</tr>
<tr>
<td>Naloxone hydrochloride</td>
<td>357-08-4</td>
<td>206-611-0</td>
<td>Not Listed</td>
<td>0.04</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Methylparaben</td>
<td>99-76-3</td>
<td>202-785-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Propylparaben</td>
<td>94-13-3</td>
<td>202-307-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary
** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:  Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact: Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters
During all fire-fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit: 2 ppm
Australia PEAK 5 ppm
Austria OEL - MAKs 7.5 mg/m³
Belgium OEL - TWA 8 mg/m³
Bulgaria OEL - TWA 8 mg/m³
Cyprus OEL - TWA 8 mg/m³
Czech Republic OEL - TWA 8 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>OEL - TWA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estonia</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Germany (DFG)</td>
<td>MAK</td>
<td>2 ppm, 3 mg/m³</td>
</tr>
<tr>
<td>Germany</td>
<td>OEL - TWA</td>
<td>2 ppm, 3.0 mg/m³</td>
</tr>
<tr>
<td>Greece</td>
<td>OEL - TWA</td>
<td>5 ppm, 7 mg/m³</td>
</tr>
<tr>
<td>Hungary</td>
<td>OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Ireland</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Italy</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Japan</td>
<td>OEL - TWA</td>
<td>2 ppm, 3.0 mg/m³</td>
</tr>
<tr>
<td>Latvia</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Lithuania</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Malta</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Netherlands</td>
<td>OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Poland</td>
<td>OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Portugal</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Romania</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Slovakia</td>
<td>OEL - TWA</td>
<td>5 ppm, 8.0 mg/m³</td>
</tr>
<tr>
<td>Slovenia</td>
<td>OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Spain</td>
<td>OEL - TWA</td>
<td>5 ppm, 7.6 mg/m³</td>
</tr>
<tr>
<td>Switzerland</td>
<td>OEL - TWA</td>
<td>2 ppm, 3.0 mg/m³</td>
</tr>
<tr>
<td>Vietnam</td>
<td>OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
</tbody>
</table>

**SODIUM CHLORIDE**

- Latvia OEL - TWA: 5 mg/m³
- Lithuania OEL - TWA: 5 mg/m³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

**Naloxone hydrochloride**

- Pfizer Occupational Exposure Band (OEB): OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

**Exposure Controls**
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Solution</th>
<th>Color:</th>
<th>Colorless</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available.</td>
<td>Odor Threshold:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

| Solvent Solubility:     | No data available               |                                  |                                |
| Water Solubility:       | No data available               |                                  |                                |
| pH:                     | 3.0-6.5                         |                                  |                                |
| Melting/Freezing Point (°C): | No data available             |                                  |                                |
| Boiling Point (°C):     | No data available               |                                  |                                |
| Partition Coefficient:  | (Method, pH, Endpoint, Value)  |                                  |                                |

HYDROCHLORIC ACID
No data available

SODIUM CHLORIDE
No data available

Methylparaben
No data available

Propylparaben
No data available

Water for Injection
No data available

Naloxone hydrochloride
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:
Autoignition Temperature (Solid) (°C): No data available
SAFETY DATA SHEET

Material Name: Naloxone Hydrochloride Injection, USP (Hospira Inc.)
Revision date: 17-Aug-2016

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: None
  Conditions to Avoid: Not determined
  Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
  Hazardous Decomposition Products: Thermal decomposition products may include carbon monoxide, carbon dioxide, oxides of nitrogen and hydrogen chloride.

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
  General Information: The information included in this section describes the potential hazards of the individual ingredients.
  Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include headache, sweating, nausea, decrease in blood pressure (hypotension), increase in blood pressure (hypertension), shortness of breath (dyspnea), increased heart rate (tachycardia), irritability, anxiety, inability to concentrate, lack of appetite.

Acute Toxicity: (Species, Route, End Point, Dose)

<table>
<thead>
<tr>
<th>Substances</th>
<th>Species</th>
<th>Route</th>
<th>End Point</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROCHLORIC ACID</td>
<td>Rat</td>
<td>Oral</td>
<td>LD 50</td>
<td>238-277 mg/kg</td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td>Rat</td>
<td>Sub-tenon injection (eye)</td>
<td>LC50/1hr</td>
<td>&gt; 42 g/m³</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Oral</td>
<td>LD 50</td>
<td>3g/kg</td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Oral</td>
<td>LD 50</td>
<td>4g/kg</td>
</tr>
<tr>
<td></td>
<td>Rabbit</td>
<td>Dermal</td>
<td>LD 50</td>
<td>&gt; 10g/kg</td>
</tr>
<tr>
<td>Naloxone hydrochloride</td>
<td>Rat</td>
<td>Oral</td>
<td>LD50</td>
<td>&gt; 1000 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Oral</td>
<td>LD50</td>
<td>&gt; 1000mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Intravenous</td>
<td>LD50</td>
<td>107mg/kg</td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Intravenous</td>
<td>LD50</td>
<td>90mg/kg</td>
</tr>
</tbody>
</table>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

| SODIUM CHLORIDE               |
|-----------------------------|----------------|
| Skin Irritation             | Rabbit Mild   |
| Eye Irritation              | Rabbit Mild   |

PZ03125
11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Naloxone hydrochloride
Embryo / Fetal Development  Rat  No route specified 8 times human dose  NOAEL  Not teratogenic
Embryo / Fetal Development  Mouse  No route specified 4 times human dose  NOAEL  Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

HYDROCHLORIC ACID
Bacterial Mutagenicity (Ames)  Salmonella  Negative
In Vivo Micronucleus  Rat  Negative

Naloxone hydrochloride
Bacterial Mutagenicity (Ames)  Positive
In Vitro Chromosome Aberration  Human Lymphocytes  Positive
Mammalian Cell Mutagenicity  HGPRT Hamster  Negative
In Vivo Chromosome Aberration  Rat Bone Marrow  Negative
In Vivo Micronucleus  Negative

Carcinogen Status:  None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID
IARC:  Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:  Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:  No data available

Persistence and Degradability:  No data available

Bio-accumulative Potential:  No data available

Mobility in Soil:  No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:  Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Water for Injection
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register:
- EU EINECS/ELINCS List: 231-791-2

Methylparaben
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 202-785-7

HYDROCHLORIC ACID
- CERCLA/SARA 313 Emission reporting: 1.0 %
- CERCLA/SARA Hazardous Substances and their Reportable Quantities:
  - 5000 lb
  - 2270 kg
- CERCLA/SARA - Section 302 Extremely Hazardous TPQs:
  - 500 lb
- CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs:
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons:
  - Schedule 5
  - Schedule 6
- EU EINECS/ELINCS List: 231-595-7

Propylparaben
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
15. REGULATORY INFORMATION

| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 202-307-7 |

Naloxone hydrochloride
- CERCLA/SARA 313 Emission reporting | Not Listed |
- California Proposition 65 | Not Listed |
- Australia (AICS): | Present |
- EU EINECS/ELINCS List | 206-611-0 |

SODIUM CHLORIDE
- CERCLA/SARA 313 Emission reporting | Not Listed |
- California Proposition 65 | Not Listed |
- Inventory - United States TSCA - Sect. 8(b) | Present |
- Australia (AICS): | Present |
- EU EINECS/ELINCS List | 231-598-3 |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3
- Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
- Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.
Revision date: 17-Aug-2016
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet